These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36029409)

  • 1. Post-translational Modifications in Brain Diseases: A Future for Biomarkers.
    Silva-Costa LC; Smith BJ
    Adv Exp Med Biol; 2022; 1382():129-141. PubMed ID: 36029409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers.
    Zhu G; Jin L; Sun W; Wang S; Liu N
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188735. PubMed ID: 35577141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human disease biomarker panels through systems biology.
    Smith BJ; Silva-Costa LC; Martins-de-Souza D
    Biophys Rev; 2021 Dec; 13(6):1179-1190. PubMed ID: 35059036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications.
    Deolankar SC; Patil AH; Koyangana SG; Subbannayya Y; Prasad TSK; Modi PK
    OMICS; 2019 Jul; 23(7):350-361. PubMed ID: 31225774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-translational modifications of pancreatic fluid proteins collected via the endoscopic pancreatic function test (ePFT).
    Paulo JA; Kadiyala V; Brizard S; Banks PA; Steen H; Conwell DL
    J Proteomics; 2013 Oct; 92():216-27. PubMed ID: 23500127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry.
    Mnatsakanyan R; Shema G; Basik M; Batist G; Borchers CH; Sickmann A; Zahedi RP
    Expert Rev Proteomics; 2018 Jun; 15(6):515-535. PubMed ID: 29893147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing disease-associated changes in post-translational modifications by mass spectrometry.
    Thygesen C; Boll I; Finsen B; Modzel M; Larsen MR
    Expert Rev Proteomics; 2018 Mar; 15(3):245-258. PubMed ID: 29376447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing mass spectrometry for the quantitative analysis of neuropeptides.
    Sauer CS; Phetsanthad A; Riusech OL; Li L
    Expert Rev Proteomics; 2021 Jul; 18(7):607-621. PubMed ID: 34375152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia.
    Smith BJ; Carregari VC
    Adv Exp Med Biol; 2022; 1400():75-87. PubMed ID: 35930227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Modifications in Neurological Disorders.
    Smith BJ; Carregari VC
    Adv Exp Med Biol; 2022; 1382():95-107. PubMed ID: 36029406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry.
    Jensen ON
    Curr Opin Chem Biol; 2004 Feb; 8(1):33-41. PubMed ID: 15036154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sub-speciating Campylobacter jejuni by proteomic analysis of its protein biomarkers and their post-translational modifications.
    Fagerquist CK; Bates AH; Heath S; King BC; Garbus BR; Harden LA; Miller WG
    J Proteome Res; 2006 Oct; 5(10):2527-38. PubMed ID: 17022624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current strategies and findings in clinically relevant post-translational modification-specific proteomics.
    Pagel O; Loroch S; Sickmann A; Zahedi RP
    Expert Rev Proteomics; 2015 Jun; 12(3):235-53. PubMed ID: 25955281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-translational modifications and their biological functions: proteomic analysis and systematic approaches.
    Seo J; Lee KJ
    J Biochem Mol Biol; 2004 Jan; 37(1):35-44. PubMed ID: 14761301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of mass spectrometry-based proteomics to understanding epigenetics.
    Noberini R; Sigismondo G; Bonaldi T
    Epigenomics; 2016 Mar; 8(3):429-45. PubMed ID: 26606673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases.
    Wei X; Li L
    Int J Clin Exp Pathol; 2009; 2(2):132-48. PubMed ID: 19079648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Techniques for studying protein heterogeneity and post-translational modifications.
    Baumann M; Meri S
    Expert Rev Proteomics; 2004 Aug; 1(2):207-17. PubMed ID: 15966815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas.
    Li J; Zhan X
    Biochim Biophys Acta Proteins Proteom; 2021 Mar; 1869(3):140584. PubMed ID: 33321259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of non-enzymatic post-translational modification derived products (PTMDPs) as biomarkers of chronic diseases.
    Gillery P; Jaisson S
    J Proteomics; 2013 Oct; 92():228-38. PubMed ID: 23459210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Interrogation in Cancer Biomarker.
    Kang UB
    Adv Exp Med Biol; 2021; 1187():305-322. PubMed ID: 33983585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.